Data from the 739 patient SIRFLOX and FOXFIRE Global studies indicate:

  • OS was significantly improved by the addition of SIRT with SIR-Spheres® Y-90 resin microspheres to first-line mFOLFOX6 chemotherapy (± bevacizumab) in mCRC patients with a Right-Sided Primary (RSP) tumour (median 22.0 vs. 17.1 months, with vs. without SIRT respectively; HR: 0.64 [95% CI: 0.46–0.89] p=0.008), which translates into a 36% reduction in the risk of death at any time compared to patients receiving chemotherapy alone.
  • No significant improvement in survival was seen from the addition of SIRT to first-line mFOLFOX6 chemotherapy for patients with Left-Sided Primary (LSP) tumours (median 24.6 vs. 26.6 months, with vs. without SIRT respectively; HR: 1.12 [95% CI: 0.92–1.37] p=0.264).

bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)

Gibbs P et al. Clin Col Cancer 2018; 17: e617-e629.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.